Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update

Radiology. 2008 Jan;246(1):11-4. doi: 10.1148/radiol.2461071267. Epub 2007 Sep 12.
No abstract available

MeSH terms

  • Contrast Media / adverse effects*
  • Fibrosis / chemically induced*
  • Fibrosis / epidemiology
  • Gadolinium
  • Gadolinium DTPA / adverse effects*
  • Heterocyclic Compounds / adverse effects*
  • Humans
  • Magnetic Resonance Imaging*
  • Meglumine / adverse effects
  • Meglumine / analogs & derivatives*
  • Organometallic Compounds / adverse effects*
  • Renal Insufficiency / complications*
  • Risk
  • United States
  • United States Food and Drug Administration*

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadoteridol
  • gadobenic acid
  • Meglumine
  • gadodiamide
  • Gadolinium
  • Gadolinium DTPA
  • gadoversetamide